The fourth member of the β 2 -integrin family of adhesion molecules, CD11d (α D β 2 ), is expressed on a wide variety of immune cells, however its function in autoimmune diseases, including EAE remains unknown. We induced EAE in wild-type and CD11d
Introduction
A critical requirement for the development of multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE) is the trafficking of immune effector cells into the central nervous system (CNS). These cells include macrophages and antigen-specific T cells which can participate in lesion formation and, in turn, demyelination (Sospedra and Martin, 2005) . There are several families of cellular adhesion molecules known to function in the trafficking of effector cells to sites of inflammation, including the CNS (Archelos et al., 1999; Butcher et al., 1999; Campbell et al., 1998; Engelhardt, 2006; von Andrian and Mackay, 2000) . In MS, the most notable of these are the α 4 integrins, specifically α 4 β 7 and α 4 β 1 , since treatment with antibody to α 4 reduces the development of new lesions, resulting in fewer clinical relapses (Miller et al., 2003) . However inhibition of α 4 integrins, by a variety of approaches, does not completely prevent disease, due most likely to the participation of other cellular adhesion molecules in the disease process (Engelhardt et al., 1998; Kent et al., 1995; Myers et al., 2005; Yednock et al., 1992) .
In addition to the α 4 integrins, members of the β 2 -integrin family, in particular CD11a and CD11b have been shown to contribute to EAE, however the results have often been contradictory. For example, treatment with anti-CD11a antibody in EAE produced results ranging from disease inhibition to exacerbation (Cannella et al., 1993; Gordon et al., 1995; Welsh et al., 1993; Willenborg et al., 1996) . Similarly, several studies have shown variable levels of protection in antibody-mediated inhibition of CD11b. Those studies demonstrating attenuated disease attributed protection largely to prevention of myelin phagocytosis (Brocke et al., 1999; Bruck, 1997; Bruck and Friede, 1990; Gordon Journal of Neuroimmunology 184 (2007) 180 -187 www.elsevier.com/locate/jneuroim
